Who are Glibenclamide and Metformin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GLIMEPIRIDE + METFORMIN, Glibenclamide + Metformin, Glimepiride and Metformin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glibenclamide-and-metformin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Glibenclamide and Metformin — Competitive Intelligence Brief

Glibenclamide and Metformin (Glibenclamide and Metformin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea + Biguanide combination. Area: Diabetes.

marketed Sulfonylurea + Biguanide combination ATP-sensitive potassium channel (Kir6.2/SUR1); AMPK and mitochondrial complex I Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Glibenclamide and Metformin (Glibenclamide and Metformin) — Takeda. Glibenclamide stimulates insulin secretion from pancreatic beta cells, while metformin reduces hepatic glucose production and improves insulin sensitivity.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Glibenclamide and Metformin TARGET	Glibenclamide and Metformin	Takeda	marketed	Sulfonylurea + Biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); AMPK and mitochondrial complex I
GLIMEPIRIDE + METFORMIN	GLIMEPIRIDE + METFORMIN	Sanofi	marketed	Sulfonylurea + biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial respiratory chain complex I
Glibenclamide + Metformin	Glibenclamide + Metformin	University of Zambia	phase 3	Sulfonylurea + Biguanide combination	ATP-sensitive potassium channel (Kir6.2/SUR1); mitochondrial complex I and AMP-activated protein kinase
Glimepiride and Metformin	Glimepiride and Metformin	Takeda	phase 3	Sulfonylurea + Biguanide combination	ATP-sensitive potassium channel (Glimepiride); Complex I of mitochondrial electron transport chain (Metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea + Biguanide combination class)

Takeda · 2 drugs in this class
University of Zambia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glibenclamide and Metformin — Competitive Intelligence Brief. https://druglandscape.com/ci/glibenclamide-and-metformin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab